Stay updated with breaking news from Cellular Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Despite Cordlife's board being made aware that one of its tanks had been exposed to irregular temperatures in June 2022, the private cord blood bank did not announce the incident at that time.
Presenters at the American Society of Hematology Annual Meeting and Exposition agreed that novel strategies, such as CRISPR and base editing, have potential to fine-tune the latest immunotherapy advancements to increase the efficacy and durability of a range of treatments.
BOSTON - Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced today that the U.S. Food and Drug Administration has approved CASGEVY , a CRISPR/Cas9 genome-edited cell therapy, for...
– Orca-T, Orca Bio’s lead investigational high-precision cell therapy, showed similar results in older patients undergoing myeloablative conditioning as seen in younger patients across disease control, non-relapse mortality and overall survival –– Orca-T in older patients given a reduced intensity conditioning regim...
Vertex and CRISPR Therapeutics have announced FDA approval for CASGEVY in treating sickle cell disease. Utilizing cutting edge CRISPR/Cas9 gene editing technology, a patient’s own genes are extracted, edited, and then reinserted to eliminate sickle cell in this new therapy.